Regulation of messenger ribonucleic acid expression for gluconeogenic enzymes during glucagon infusions into lactating cows.
The effects of glucagon infusions on expression of mRNA for enzymes that regulate gluconeogenesis were studied in lactating cows. Normal cows and cows with fatty liver that were susceptible to ketosis were assigned to either glucagon-treated or control groups. Glucagon at 0 or 10 mg/d was infused for 14 d beginning at d 21 postpartum. In normal cows, glucagon infusions increased concentrations of both plasma glucagon and glucose, which caused plasma insulin to increase. Consequently, hepatic phosphoenolpyruvate carboxykinase mRNA decreased during wk 1 of glucagon infusions. Glucagon infusions into cows with fatty liver also increased plasma glucagon and glucose, but concentrations of plasma insulin and hepatic phosphoenolpyruvate carboxykinase mRNA did not change. More phosphoenolpyruvate carboxykinase mRNA was present in the livers of cows with fatty liver than in livers of normal cows. In a follow-up experiment with midlactation cows, 3.5-h infusions of glucagon at 14 mg/d increased plasma glucose and insulin and decreased plasma nonesterified fatty acids and hepatic glycogen. Hepatic phosphoenolpyruvate carboxykinase mRNA was decreased 41%, pyruvate carboxylase mRNA was increased 50%, but fructose-1,6-bisphosphatase mRNA did not change. We conclude that the expression of the hepatic phosphoenolpyruvate carboxykinase gene in normal cows is inhibited by insulin to balance elevated carbohydrate status during glucagon infusions; however, inhibited expression of hepatic phosphoenolpyruvate carboxykinase mRNA probably is not involved in the pathogenesis of lactation ketosis.
She
P
P
Department of Animal Science, Iowa State University, Ames 50011-3150, USA.
Lindberg
G L
GL
Hippen
A R
AR
Beitz
D C
DC
Young
J W
JW
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D015152:Blotting, Northern; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D005934:Glucagon / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D005943:Gluconeogenesis / Q000235:genetics*; D007662:Ketosis / Q000188:drug therapy / Q000662:veterinary*; D007774:Lactation; D008099:Liver / Q000201:enzymology; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000235:genetics; D011766:Pyruvate Carboxylase / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism*
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D012333:RNA, Messenger; D005934:Glucagon; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D011766:Pyruvate Carboxylase; D020155:3-Hydroxybutyric Acid